Joseph A. Sparano, MD
Professor of Medicine and Women’s Health
Albert Einstein College of Medicine
Associate Chairman, Clinical Research
Department of Oncology
Montefiore Medical Center
Director, Breast Evaluation Center
Montefiore-Einstein Cancer Center
Bronx, New York
Mobile HTML (For PDA)
Over the past decade, insights into the origins and biology of breast cancer have reshaped our understanding of this disease and generated advances in clinical care. The 30th Annual San Antonio Breast Cancer Symposium (SABCS), a collaborative effort of the San Antonio Cancer Institute and Baylor College of Medicine, was held on December 13-16, 2007, in San Antonio, Texas, and brought together more than 8,600 health care professionals from the US and 84 other countries.
This monograph will review selected pivotal data presented during SABCS 2007, including a discussion of new clinical trial results with systemic adjuvant therapy in advanced breast cancer; new methods in imaging and detection of breast cancer, including molecular imaging; new frontiers in genomic profiling and individualization of breast cancer therapy; advances in local therapy of early breast cancer; and new insights into the negative effects of endocrine therapy on bone mineral density (BMD), and approaches to the prevention of BMD changes and their clinical consequences
. Target Audience
This educational activity is designed to meet the needs of oncologists, advanced practice oncology nurses and pharmacists interested in the prevention or treatment of breast cancer.
Upon completion of this educational activity, the participant should be able to:
Discuss emerging treatment approaches for early and advanced breast cancer
Describe emerging technologies for the individualization of the treatment of breast cancer, including genomic profiling for pharmacotherapy
Describe innovations in breast cancer detection and disease monitoring
Discuss approaches toward the prevention of the loss of bone mineral density during adjuvant endocrine therapy of breast cancer
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
This educational activity may contain discussion of published and/or investigational uses of oncology agents. Some uses may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Joseph A. Sparano, MD discloses that he is on speakers’ bureaus for Genentech, Inc. and sanofi-aventis, is a product consultant for Bristol-Myers Squibb Company, sanofi-aventis, and Johnson and Johnson, and is a member of advisory committees for Bristol-Myers Squibb Company, sanofi-aventis, and Eisai Inc.
Pharmacists: AKH Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program has been assigned the Universal Program Number 077-999-08-015-H01-P and is acceptable for 1.5 contact hours ( 0.15 CEUs).
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and polices of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Inc. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
AKH Inc. designates this educational activity for 1.5 contact hours.
This activity should take approximately 90 minutes to complete. Credit is awarded to participants who complete the evaluation and score 70% or better on the post-test online. One retake is permitted. A statement of credit can be printed immediately upon successful completion. Commercial Support Statements
Supported by an educational grant from Abraxis BioScience and AstraZeneca.